86 results
8-K
EX-10.1
DMKPQ
DMK Pharmaceuticals Corp
3 Aug 23
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
4:59pm
health and the environment (“Environmental Law”), except for violations and liabilities which, individually or in the aggregate, would not have a Material … or into the environment surrounding any such property of any Hazardous Substances with respect to which the Company or any Subsidiary has knowledge, except
DEFM14A
DMKPQ
DMK Pharmaceuticals Corp
13 Apr 23
Proxy related to merger
4:52pm
.
RISK FACTORS
The combined company will be faced with a market environment that cannot be predicted and that involves significant risks, many … accounting firm. Failure to achieve and maintain an effective internal control environment could have a material adverse effect on the combined company’s
DEFA14A
EX-10.1
msievubc
6 Jul 22
Additional proxy soliciting materials
6:04am
8-K
EX-10.1
31la4117zrv2pexibi74
6 Jul 22
Entry into a Material Definitive Agreement
6:04am
8-K
EX-14.1
k65aq 1eq
18 Feb 22
Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
4:43pm
8-K
EX-1.1
jul9n
29 Jan 21
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
5:10pm
8-K
EX-99.1
p6owzj8 g63x
5 Oct 20
Report of Independent Registered Public Accounting Firm
5:25pm
8-K
EX-99.2
y2dxbz fs80bzh
5 Oct 20
Report of Independent Registered Public Accounting Firm
5:25pm
8-K
EX-1.1
z5bso8uxuglozkwyf
18 Sep 20
Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock
4:53pm